{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:10:32Z","timestamp":1788898232253,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.healun.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T07:30:43Z","timestamp":1410334243000},"page":"658-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy"],"prefix":"10.1016","volume":"34","author":[{"given":"Margot K.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.U.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2014.09.006_bib1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0002-8703(95)90362-3","article-title":"Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients","volume":"130","author":"Arbustini","year":"1995","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2014.09.006_bib2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2014.09.006_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2014.09.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2014.09.006_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.healun.2008.05.016","article-title":"Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy","volume":"27","author":"Lacy","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib7","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2007.08.028","article-title":"Evaluation and management of the cardiac amyloidosis","volume":"50","author":"Selvanayagam","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2014.09.006_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1600-6143.2008.02162.x","article-title":"Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis","volume":"8","author":"Hamour","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0002-9149(85)91028-8","article-title":"Electrophysiologic evaluation of the cardiac conduction system and its autonomic regulation in familial amyloid polyneuropathy","volume":"56","author":"Bergfeldt","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.healun.2014.09.006_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","article-title":"Cardiac transplantation for amyloid heart disease: the United Kingdom experience","volume":"23","author":"Dubrey","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2014.09.006_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","article-title":"Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis","volume":"33","author":"Gray Gilstrap","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","article-title":"Outcome of heart transplantation in patients with amyloid cardiomyopathy","volume":"24","author":"Kpodonu","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.healun.2012.09.018","article-title":"Outcomes of adults with restrictive cardiomyopathy after heart transplantation","volume":"31","author":"DePasquale","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.healun.2012.10.014","article-title":"Should we avoid heart transplantation in cardiomyopathy due to radiotherapy\/chemotherapy or amyloidosis? The devil is in the details","volume":"31","author":"Nohria","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurjhf\/hfp121","article-title":"Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis","volume":"11","author":"Kristen","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2014.09.006_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.healun.2011.09.010","article-title":"Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies","volume":"31","author":"Varr","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.healun.2014.09.006_bib19","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients","volume":"101","author":"Moreau","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.healun.2014.09.006_bib21","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2014.09.006_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","article-title":"High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement","volume":"119","author":"Madan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/TP.0b013e3181f10edb","article-title":"Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure","volume":"90","author":"Dey","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2014.09.006_bib26","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2014.09.006_bib27","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib28","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib29","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.healun.2014.09.006_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2014.09.006_bib31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","article-title":"Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis","volume":"158","author":"Connors","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2014.09.006_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.healun.2014.09.006_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2014.09.006_bib34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004390050199","article-title":"Revised transthyretin Ile 122 allele frequency in African-Americans","volume":"98","author":"Jacobson","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.healun.2014.09.006_bib35","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.healun.2014.09.006_bib36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2014.09.006_bib37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jchf.2013.11.005","article-title":"Regional differences in recipient waitlist time and pre- and post-transplant mortality after the 2006 United Network for Organ Sharing policy changes in the donor heart allocation algorithm","volume":"2","author":"Schulze","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.healun.2014.09.006_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.111.964247","article-title":"Decline in heart transplant wait list mortality in the United States following broader regional sharing of donor hearts","volume":"5","author":"Singh","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.healun.2014.09.006_bib39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/CIRCHEARTFAILURE.111.966135","article-title":"Heart allocation in the United States: intended and unintended consequences","volume":"5","author":"Givertz","year":"2012","journal-title":"Circ Heart Failure"},{"key":"10.1016\/j.healun.2014.09.006_bib40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jchf.2014.01.002","article-title":"Time for change in United States donor heart allocation policy","volume":"2","author":"Kobashigawa","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.healun.2014.09.006_bib41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtcvs.2010.04.029","article-title":"Standard versus bicaval techniques for orthotopic heart transplantation: an analysis of the United Network for Organ Sharing database","volume":"140","author":"Davies","year":"2010","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324981401314X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324981401314X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:28:51Z","timestamp":1760948931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105324981401314X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S105324981401314X"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2014.09.006","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}